1.40
price up icon1.45%   0.02
pre-market  Pre-market:  1.40  
loading
Neumora Therapeutics Inc stock is traded at $1.40, with a volume of 1.47M. It is up +1.45% in the last 24 hours and down -17.16% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.38
Open:
$1.38
24h Volume:
1.47M
Relative Volume:
0.49
Market Cap:
$226.77M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.5524
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-7.89%
1M Performance:
-17.16%
6M Performance:
-88.36%
1Y Performance:
-90.55%
1-Day Range:
Value
$1.36
$1.435
1-Week Range:
Value
$1.26
$1.49
52-Week Range:
Value
$1.26
$17.19

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name
Name
Neumora Therapeutics Inc
Name
Phone
(857) 760-0900
Name
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NMRA
Neumora Therapeutics Inc
1.40 226.77M 0 -274.18M -198.33M -2.5346
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-10-25 Downgrade William Blair Outperform → Mkt Perform
Mar-07-25 Downgrade Guggenheim Buy → Neutral
Mar-07-25 Downgrade Stifel Buy → Hold
Jan-02-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-05-24 Downgrade JP Morgan Overweight → Neutral
Oct-01-24 Initiated H.C. Wainwright Buy
Jul-22-24 Initiated Needham Buy
Jul-08-24 Initiated Mizuho Outperform
Dec-12-23 Initiated Deutsche Bank Hold
Oct-10-23 Initiated BofA Securities Buy
Oct-10-23 Initiated Guggenheim Buy
Oct-10-23 Initiated JP Morgan Overweight
Oct-10-23 Initiated RBC Capital Mkts Outperform
Oct-10-23 Initiated Stifel Buy
Oct-10-23 Initiated William Blair Outperform
View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

pulisher
Mar 13, 2025

ROSEN, THE FIRST FILING FIRM, Encourages Neumora - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph

Mar 13, 2025
pulisher
Mar 13, 2025

ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 13, 2025

Lead Plaintiff Deadline Approaching in NMRA: Kessler Topaz - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Lead Plaintiff Deadline Approaching in NMRA: Kessler Topaz Meltzer & Check, LLP Reminds Investors a Securities Fraud Class Action Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Neumora Therapeutics, Inc.(NMRA) Shareholders - ACCESS Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Class Action Filed Against Neumora Therapeutics, Inc. - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - PR Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Mar 13, 2025
pulisher
Mar 13, 2025

Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire

Mar 13, 2025
pulisher
Mar 12, 2025

Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) See - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Lowey Dannenberg Notifies Neumora Therapeutics, Inc. - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

NMRA CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investorsa Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) | FinancialContent - Financial Content

Mar 12, 2025
pulisher
Mar 12, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Mar 12, 2025
pulisher
Mar 12, 2025

2025-03-12 | Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing

Mar 12, 2025
pulisher
Mar 11, 2025

2025-03-11 | Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing

Mar 11, 2025
pulisher
Mar 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNMRA - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Mar 11, 2025
pulisher
Mar 11, 2025

Equities Analysts Issue Forecasts for NMRA Q1 Earnings - MarketBeat

Mar 11, 2025
pulisher
Mar 11, 2025

Neumora Therapeutics (NASDAQ:NMRA) Downgraded to Market Perform Rating by William Blair - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN

Mar 10, 2025
pulisher
Mar 10, 2025

NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 10, 2025

2025-03-10 | Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:NMRA | Press Release - Stockhouse Publishing

Mar 10, 2025
pulisher
Mar 10, 2025

Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNMRA - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 10, 2025

2025-03-10 | NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:NMRA | Press Release - Stockhouse Publishing

Mar 10, 2025
pulisher
Mar 10, 2025

Neumora Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNMRA - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 10, 2025

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - Morningstar

Mar 10, 2025
pulisher
Mar 10, 2025

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - StreetInsider.com

Mar 10, 2025
pulisher
Mar 10, 2025

Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 10, 2025

Neumora stock rating cut to Market Perform at William Blair - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Neumora stock holds Buy rating and $18 target from H.C. Wainwright - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Mar 10, 2025
pulisher
Mar 10, 2025

Neumora Therapeutics (NASDAQ:NMRA) Downgraded by William Blair to Market Perform - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform -March 10, 2025 at 07:50 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds ... - The Bakersfield Californian

Mar 10, 2025
pulisher
Mar 10, 2025

Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar

Mar 10, 2025
pulisher
Mar 10, 2025

HC Wainwright Issues Optimistic Estimate for NMRA Earnings - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

What is William Blair's Forecast for NMRA Q1 Earnings? - MarketBeat

Mar 09, 2025
pulisher
Mar 09, 2025

2025-03-09 | Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing

Mar 09, 2025
pulisher
Mar 09, 2025

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph

Mar 09, 2025
pulisher
Mar 09, 2025

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora - GlobeNewswire

Mar 09, 2025
pulisher
Mar 09, 2025

Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Mar 09, 2025
pulisher
Mar 09, 2025

2025-03-09 | NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:NMRA | Press Release - Stockhouse Publishing

Mar 09, 2025
pulisher
Mar 09, 2025

Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Lowered by Guggenheim - Defense World

Mar 09, 2025

Neumora Therapeutics Inc Stock (NMRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Neumora Therapeutics Inc Stock (NMRA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BERNS PAUL L
See Remarks
Feb 18 '25
Sale
1.69
13,871
23,468
7,405,004
Milligan Michael Lee
See Remarks
Feb 18 '25
Sale
1.69
1,978
3,351
22,470
Aurora Daljit Singh
Chief Strategy Officer
Feb 18 '25
Sale
1.68
8,565
14,347
88,935
Lenz Robert A.
Head of R&D
Feb 18 '25
Sale
1.67
5,614
9,383
309,092
Pinto Joshua
President
Feb 18 '25
Sale
1.67
8,048
13,477
76,952
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):